Dual-task Training to Prevent Cognitive Decline in Community-dwelling Older Adults: A Pilot Pragmatic RCT
NCT06648707, Not applicable, Recruiting, The University of Hong Kong
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Dual-task Training to Prevent Cognitive Decline in Community-dwelling Older Adults: A Pilot Pragmatic RCT | ClinicalTrials.gov |
| NCT number | NCT06648707 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 93 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The University of Hong Kong | ClinicalTrials.gov |
| Conditions | Community-dwelling Seniors | ClinicalTrials.gov |
| Interventions | Dual-task training | ClinicalTrials.gov |
| First posted | 2024-10-18 | ClinicalTrials.gov |
| Last updated | 2024-12-06 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Recruitment rate | After baseline, before randomization | Recruitment rate is defined as the number of participants agreed to join the study before randomization divided by the number of potential participants who completed recruitment briefing. | ClinicalTrials.gov |
| Primary | Attendance rate | 6 weeks after baseline for intervention group, 12 weeks after baseline for waitlist control group. | Attendance rate is defined as the number of attended intervention sessions collected in attendance log divided by the number of planned intervention sessions. | ClinicalTrials.gov |
| Primary | Retention rate | 6 weeks after baseline for intervention group, 12 weeks after baseline for waitlist control group. | Retention rate is defined as the number of participants completing the post-intervention assessment divided by the number of participants at baseline. | ClinicalTrials.gov |
| Primary | Satisfaction rate | 6 weeks after baseline for intervention group, 12 weeks after baseline for waitlist control group. | Satisfaction to the project will be measured by a question using 5-point Likert scale (very satisfactory to very unsatisfactory). Satisfaction rate is defined as the number of participants rating the intervention a score of ≥4 out of 5 divided by the number of participants started intervention. | ClinicalTrials.gov |
| Secondary | Completion rate of the interventionist | End of study, up to 2 years | The number of nominated staff/volunteers considered as completing the project divided by the total number of nominated staff/volunteers | ClinicalTrials.gov |
| Secondary | Time to recruit target sample size | Before baseline | The time needed to recruit target sample size is defined as the time taken to recruit required sample size in each centre. | ClinicalTrials.gov |
| Secondary | Factors influencing older adults' decision to participate and staff of the community centre to organise the activity | At the end of recruitment briefing, before baseline | Reasons of the older adults and staff of the community centres for joining or not joining the study | ClinicalTrials.gov |
| Secondary | Change from baseline subjective memory complaints at 6 weeks | 6 weeks after baseline | Subjective memory complaints will be measured by the 27-item Memory Inventory in Chinese (Lui et al., 2006). Participants response on the frequency of complaints related to daily living in the past month, using 0 (none) to 4 (continuously). The scale ranges from 0 to 108, higher score indicates more memory complaints. | ClinicalTrials.gov |
| Secondary | Change from baseline subjective memory complaints at 12 weeks | 12 weeks after baseline, only for waitlist control group | Subjective memory complaints will be measured by the 27-item Memory Inventory in Chinese (Lui et al., 2006). Participants response on the frequency of complaints related to daily living in the past month, using 0 (none) to 4 (continuously). The scale ranges from 0 to 108, higher score indicates more memory complaints. | ClinicalTrials.gov |
| Secondary | Change from baseline working memory at 6 weeks | 6 weeks after baseline | Working memory will be measured by Digit Span Test (Leung et al., 2011). The participants will repeat the digits series which are gradually longer. In both the forward and the backward test, the longer the series, the better the condition. | ClinicalTrials.gov |
| Secondary | Change from baseline working memory at 12 weeks | 12 weeks after baseline, only for waitlist control group | Working memory will be measured by Digit Span Test (Leung et al., 2011). The participants will repeat the digits series which are gradually longer. In both the forward and the backward test, the longer the series, the better the condition. | ClinicalTrials.gov |
| Secondary | Change from baseline executive function at 6 weeks | 6 weeks after baseline | Executive function will be measured by Chinese version of the Victoria Stroop Test (Lee and Chan, 2000). The completion time and number of errors that the participants made in naming the colour in the presence of different stimuli (number dots, words unrelated to color, words related to color) will be recorded, with more time and errors as worse condition. | ClinicalTrials.gov |
| Secondary | Change from baseline executive function at 12 weeks | 12 weeks after baseline, only for waitlist control group | Executive function will be measured by Chinese version of the Victoria Stroop Test (Lee and Chan, 2000). The completion time and number of errors that the participants made in naming the colour in the presence of different stimuli (number dots, words unrelated to color, words related to color) will be recorded, with more time and errors as worse condition. | ClinicalTrials.gov |
| Secondary | Change from baseline cognitive status at 6 weeks | 6 weeks after baseline | Cognitive status will be measured by the Montreal Cognitive Assessment 5-Minutes (Hong Kong Version) (HK-MoCA 5-Min) protocol. The validated assessment test covers four domains: attention, executive functions/language, orientation, and memory (Yeung et al., 2014). The total score ranges from 0 to 30; a higher score indicates better cognitive status. | ClinicalTrials.gov |
| Secondary | Change from baseline cognitive status at 12 weeks | 12 weeks after baseline, only for waitlist control group | Cognitive status will be measured by the Montreal Cognitive Assessment 5-Minutes (Hong Kong Version) (HK-MoCA 5-Min) protocol. The validated assessment test covers four domains: attention, executive functions/language, orientation, and memory (Yeung et al., 2014). The total score ranges from 0 to 30; a higher score indicates better cognitive status. | ClinicalTrials.gov |
| Secondary | Qualitative feedback | At the end of the study, up to 2 years | Qualitative feedback on facilitators and barriers of organising the activity will be collected from one representative of each participating centre by semi-structured interview. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)